Видео ютуба по тегу Deletion 17P

Deletion 17p in Myeloma: Key Facts You Should Know - del (17p)
Deletion 17p in Myeloma: Key Facts You Should Know - del (17p)
Paul Barr, MD: Principle Treatment Options for Patients With a 17p Deletion
Paul Barr, MD: Principle Treatment Options for Patients With a 17p Deletion
Managing multiple myeloma patients with del(17p)
Managing multiple myeloma patients with del(17p)
Why is 17p deletion (17p-) considered to be a poor prognostic factor for myeloma patients?
Why is 17p deletion (17p-) considered to be a poor prognostic factor for myeloma patients?
Case 2: Newly Diagnosed CLL; Del(17p)
Case 2: Newly Diagnosed CLL; Del(17p)
Ibrutinib for CLL with Deletion 17p
Ibrutinib for CLL with Deletion 17p
Treatment options for the young CLL patient with deletion 17p: Do they need a different approach?
Treatment options for the young CLL patient with deletion 17p: Do they need a different approach?
TP53 and Deletion 17p as Prognostic Factors in CLL
TP53 and Deletion 17p as Prognostic Factors in CLL
CLL: Optimal approaches for patients with deletion 17p
CLL: Optimal approaches for patients with deletion 17p
Zanubrutinib Combined with Venetoclax for CLL Patients with Deletion 17p - Dr. Constantine Tam
Zanubrutinib Combined with Venetoclax for CLL Patients with Deletion 17p - Dr. Constantine Tam
Case 3: Treatment for Relapsed Myeloma with 17p Deletion
Case 3: Treatment for Relapsed Myeloma with 17p Deletion
Case 2: Choosing Treatment for CLL With Del(17p)
Case 2: Choosing Treatment for CLL With Del(17p)
If deletion 17 p is not detected at diagnosis, can it develop later in myeloma? #myeloma
If deletion 17 p is not detected at diagnosis, can it develop later in myeloma? #myeloma
The importance of del(17p) as a prognostic factor in myeloma
The importance of del(17p) as a prognostic factor in myeloma
Treatment recommendations for patients with CLL with del(17p) and TP53 aberrations
Treatment recommendations for patients with CLL with del(17p) and TP53 aberrations
Chronic Lymphocytic Leukaemia (CLL) Understanding 17p Deletion and Your Path to Treatment
Chronic Lymphocytic Leukaemia (CLL) Understanding 17p Deletion and Your Path to Treatment
Dr. Wierda on Treating CLL with 17p Deletion
Dr. Wierda on Treating CLL with 17p Deletion
Defining high-risk CLL: known and emerging mutations
Defining high-risk CLL: known and emerging mutations
EHA 17: Best treatment for chronic lymphocytic leukaemia with 17p deletion - Prof Michael Keating
EHA 17: Best treatment for chronic lymphocytic leukaemia with 17p deletion - Prof Michael Keating
CLL Prognosis and Treatment Options
CLL Prognosis and Treatment Options
Key prognostic markers in CLL: TP53, del(17p), and high complexity karyotype
Key prognostic markers in CLL: TP53, del(17p), and high complexity karyotype
Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation
Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation
Myeloma transplantation: 17p deletions & 4;14 translocations
Myeloma transplantation: 17p deletions & 4;14 translocations
Case 2: 17p-Deleted CLL Progressing on Ibrutinib Therapy
Case 2: 17p-Deleted CLL Progressing on Ibrutinib Therapy
The impact of gene mutations on prognosis in CLL
The impact of gene mutations on prognosis in CLL